A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Tanezumab (Primary) ; Tramadol
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 16 Jan 2019 to 8 Jan 2019.
    • 31 Aug 2017 This trial was discontinued in Denmark, according to European Clinical Trials Database.
    • 07 Jul 2017 Planned primary completion date changed from 25 Oct 2017 to 17 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top